Indaptus Therapeutics (NASDAQ:INDP) Trading 22.4% Higher – Here’s What Happened

Posted by Stanley Muller on Jun 19th, 2026

Shares of Indaptus Therapeutics, Inc. (NASDAQ:INDP – Get Free Report) traded up 22.4% during trading on Wednesday . The company traded as high as $4.46 and last traded at $4.5540. 404,040 shares changed hands during trading, a decline of 29% from the average daily volume of 565,461 shares. The stock had previously closed at $3.72.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Indaptus Therapeutics in a research report on Tuesday, April 21st. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has an average rating of “Sell”.

Read Our Latest Stock Report on INDP

Indaptus Therapeutics Stock Performance

The firm has a market cap of $441.64 million, a PE ratio of -0.25 and a beta of 1.25. The stock has a fifty day moving average price of $2.45 and a 200-day moving average price of $2.29.

Indaptus Therapeutics (NASDAQ:INDP – Get Free Report) last posted its earnings results on Friday, May 15th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.87) by $1.64.

Hedge Funds Weigh In On Indaptus Therapeutics

An institutional investor recently bought a new position in Indaptus Therapeutics stock. Virtu Financial LLC bought a new stake in shares of Indaptus Therapeutics, Inc. (NASDAQ:INDP – Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 18,997 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned approximately 1.72% of Indaptus Therapeutics at the end of the most recent quarter. 7.06% of the stock is currently owned by institutional investors.

Indaptus Therapeutics Company Profile

(Get Free Report)

Indaptus Therapeutics, Inc, is a clinical-stage biotechnology company focused on developing novel cell- and exosome-based immunotherapies for oncology and infectious diseases. Utilizing its proprietary Natural Killer (NK) Cell Platform, Indaptus engineers allogeneic NK cells with enhanced cytotoxicity and targeted tumor recognition. The company’s Exo-NK Therapeutics program further leverages NK cell–derived exosomes to deliver bioactive molecules and amplify immune responses against disease.

Indaptus’ pipeline includes multiple preclinical candidates that integrate chimeric antigen receptor (CAR) technology with NK cells and exosomes to address hematologic malignancies and solid tumors.